Lanean...

Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions

Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-yea...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Endocrinol (Lausanne)
Egile Nagusiak: Syro, Luis V., Rotondo, Fabio, Camargo, Mauricio, Ortiz, Leon D., Serna, Carlos A., Kovacs, Kalman
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2018
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6013558/
https://ncbi.nlm.nih.gov/pubmed/29963012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2018.00318
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!